These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 27678331

  • 1. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L.
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [Abstract] [Full Text] [Related]

  • 2. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

  • 3. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
    Grabinski N, Ewald F.
    Invest New Drugs; 2014 Dec; 32(6):1096-104. PubMed ID: 25081321
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
    Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS.
    J Natl Cancer Inst; 2008 Aug 06; 100(15):1092-103. PubMed ID: 18664652
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.
    Breast Cancer Res; 2014 May 05; 16(3):R45. PubMed ID: 24887236
    [Abstract] [Full Text] [Related]

  • 13. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L.
    Clin Cancer Res; 2015 Dec 15; 21(24):5519-31. PubMed ID: 26296355
    [Abstract] [Full Text] [Related]

  • 14. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
    Zhang L, Ngo JA, Wetzel MD, Marchetti D.
    Neoplasia; 2015 Jan 15; 17(1):101-13. PubMed ID: 25622903
    [Abstract] [Full Text] [Related]

  • 15. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF, El-Kalaawy AM, Abdel Latif NS, Rashed LA, Philoppes JN.
    Eur J Med Chem; 2021 Mar 15; 214():113222. PubMed ID: 33545637
    [Abstract] [Full Text] [Related]

  • 16. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 15; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 17. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.
    Irie H, Ito K, Fujioka Y, Oguchi K, Fujioka A, Hashimoto A, Ohsawa H, Tanaka K, Funabashi K, Araki H, Kawai Y, Shimamura T, Wadhwa R, Ohkubo S, Matsuo K.
    Mol Cancer Ther; 2019 Apr 15; 18(4):733-742. PubMed ID: 30787176
    [Abstract] [Full Text] [Related]

  • 18. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
    Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, Zhao P, Wang J, Wang C, Weisberg EL, Gray NS, Yun CH, Liu J, Chen L, Liu Q.
    Oncotarget; 2015 Oct 13; 6(31):31313-22. PubMed ID: 26375053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.